Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma
Findings from the CEPHEUS study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1631 results
EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel
New indication concerns treatment of adult patients with relapsed or refractory follicular lymphoma after at least two lines of systemic therapy
FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer
Evidence for efficacy is based on the results from the TROPION-Breast01 study
Strong Independent Association of TILs with OS for Patients with ERBB2-positive Early Breast Cancer
Findings from updated analysis of the ShortHER study
Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL
Findings from the AMPLIFY study
Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus Chemotherapy in Patients with Resectable NSCLC
Findings from the CheckMate 816 study
FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma
Evidence for efficacy is based on the results from the ECHO study
EMA Recommends Granting a Marketing Authorisation for Datopotamab Deruxtecan
It is indicated for the treatment of patients with previously treated unresectable or metastatic HR-positive, HER2-negative breast cancer
Zenocutuzumab Shows Efficacy in Patients with Advanced NRG1 Fusion-positive Cancers
Findings from the eNRGy study
Less Frequent Mammographic Surveillance Non-inferior Compared with Annual Mammograms After Diagnosis of Breast Cancer in Women Aged 50 Years or Older
Findings from the Mammo-50 study
First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR in Patients with BRAF V600E-mutated mCRC
Findings from the BREAKWATER study
EMA Recommends Granting a Marketing Authorisation for Tisotumab Vedotin
It is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy